{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T14:16:50Z","timestamp":1789654610028,"version":"4.0.1"},"reference-count":60,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2021,6,1]],"date-time":"2021-06-01T00:00:00Z","timestamp":1622505600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,6,1]],"date-time":"2021-06-01T00:00:00Z","timestamp":1622505600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,4,2]],"date-time":"2021-04-02T00:00:00Z","timestamp":1617321600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100006451","name":"Hospices Civils de Lyon","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100006451","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["esmoopen.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["ESMO Open"],"published-print":{"date-parts":[[2021,6]]},"DOI":"10.1016\/j.esmoop.2021.100125","type":"journal-article","created":{"date-parts":[[2021,4,23]],"date-time":"2021-04-23T00:01:43Z","timestamp":1619136103000},"page":"100125","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":49,"title":["Issues and limitations of available biomarkers for fluoropyrimidine-based chemotherapy toxicity, a narrative review of the literature"],"prefix":"10.1016","volume":"6","author":[{"given":"K.","family":"Hodroj","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D.","family":"Barthelemy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.-C.","family":"Lega","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G.","family":"Grenet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.-C.","family":"Gagnieu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T.","family":"Walter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Guitton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L.","family":"Payen-Gay","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"3-4","key":"10.1016\/j.esmoop.2021.100125_bib1","doi-asserted-by":"crossref","first-page":"620","DOI":"10.1038\/sj.bjc.6690097","article-title":"Profound variation in dihydropyrimidine dehydrogenase activity in human blood cells: major implications for the detection of partly deficient patients","volume":"79","author":"Van Kuilenburg","year":"1999","journal-title":"Br J Cancer"},{"issue":"8","key":"10.1016\/j.esmoop.2021.100125_bib3","first-page":"2203","article-title":"Clinical pharmacokinetics of 5-fluorouracil and its metabolites in plasma, urine, and bile","volume":"47","author":"Heggie","year":"1987","journal-title":"Cancer Res"},{"key":"10.1016\/j.esmoop.2021.100125_bib4","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/j.ejca.2018.07.009","article-title":"Pharmacogenetic analyses of 2183 patients with advanced colorectal cancer; potential role for common dihydropyrimidine dehydrogenase variants in toxicity to chemotherapy","volume":"102","author":"Madi","year":"2018","journal-title":"Eur J Cancer"},{"issue":"4","key":"10.1016\/j.esmoop.2021.100125_bib6","doi-asserted-by":"crossref","first-page":"301","DOI":"10.2217\/pgs-2017-0303","article-title":"Improving decision making on DPYD and UGT1A1\u221728 patients\u2019 profiling with an innovative reimbursement strategy","volume":"19","author":"Roncato","year":"2018","journal-title":"Pharmacogenomics"},{"key":"10.1016\/j.esmoop.2021.100125_bib7","doi-asserted-by":"crossref","first-page":"1609","DOI":"10.3389\/fphar.2019.01609","article-title":"DPD testing before treatment with fluoropyrimidines in the Amsterdam UMCs: an evaluation of current pharmacogenetic practice","volume":"10","author":"Martens","year":"2020","journal-title":"Front Pharmacol"},{"issue":"12","key":"10.1016\/j.esmoop.2021.100125_bib9","first-page":"4705","article-title":"Clinical implications of dihydropyrimidine dehydrogenase (DPD) deficiency in patients with severe 5-fluorouracil-associated toxicity: identification of new mutations in the DPD gene","volume":"6","author":"van Kuilenburg","year":"2000","journal-title":"Clin Cancer Res"},{"issue":"2","key":"10.1016\/j.esmoop.2021.100125_bib10","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1016\/j.canlet.2006.09.006","article-title":"5-Fluorouracil-related severe toxicity: a comparison of different methods for the pretherapeutic detection of dihydropyrimidine dehydrogenase deficiency","volume":"249","author":"Boisdron-Celle","year":"2007","journal-title":"Cancer Lett"},{"issue":"4","key":"10.1016\/j.esmoop.2021.100125_bib11","doi-asserted-by":"crossref","first-page":"1105","DOI":"10.1200\/JCO.1999.17.4.1105","article-title":"Correlation between uracil and dihydrouracil plasma ratio, fluorouracil (5-FU) pharmacokinetic parameters, and tolerance in patients with advanced colorectal cancer: a potential interest for predicting 5-FU toxicity and determining optimal 5-FU dosage","volume":"17","author":"Gamelin","year":"1999","journal-title":"J\u00a0Clin Oncol"},{"issue":"5","key":"10.1016\/j.esmoop.2021.100125_bib12","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1038\/nrc1074","article-title":"5-fluorouracil: mechanisms of action and clinical strategies","volume":"3","author":"Longley","year":"2003","journal-title":"Nat Rev Cancer"},{"issue":"9","key":"10.1016\/j.esmoop.2021.100125_bib13","doi-asserted-by":"crossref","first-page":"3142","DOI":"10.1111\/cas.14532","article-title":"5-Fluorouracil resistance mechanisms in colorectal cancer: from classical pathways to promising processes","volume":"111","author":"Blondy","year":"2020","journal-title":"Cancer Sci"},{"issue":"3","key":"10.1016\/j.esmoop.2021.100125_bib14","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1177\/0091270010396710","article-title":"Time-dependent pharmacokinetics of 5-fluorouracil and association with treatment tolerability in the adjuvant setting of colorectal cancer","volume":"52","author":"Ibrahim","year":"2012","journal-title":"J\u00a0Clin Pharmacol"},{"issue":"2","key":"10.1016\/j.esmoop.2021.100125_bib15","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1007\/s00280-002-0526-3","article-title":"Correlation between clinicopathologic factors and kinetics of metabolic enzymes for 5-fluorouracil given to patients with colon carcinoma by two different dosage regimens","volume":"51","author":"Katsumata","year":"2003","journal-title":"Cancer Chemother Pharmacol"},{"issue":"4","key":"10.1016\/j.esmoop.2021.100125_bib16","doi-asserted-by":"crossref","first-page":"215","DOI":"10.2165\/00003088-198916040-00002","article-title":"Clinical pharmacology of 5-fluorouracil","volume":"16","author":"Diasio","year":"1989","journal-title":"Clin Pharmacokinet"},{"issue":"10","key":"10.1016\/j.esmoop.2021.100125_bib17","first-page":"4900","article-title":"Dihydrofluorouracil, a fluorouracil catabolite with antitumor activity in murine and human cells","volume":"45","author":"Diasio","year":"1985","journal-title":"Cancer Res"},{"issue":"2","key":"10.1016\/j.esmoop.2021.100125_bib18","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1007\/s00280-020-04208-8","article-title":"Population pharmacokinetic and pharmacodynamic modeling of capecitabine and its metabolites in breast cancer patients","volume":"87","author":"Lunar","year":"2021","journal-title":"Cancer Chemother Pharmacol"},{"issue":"12","key":"10.1016\/j.esmoop.2021.100125_bib19","doi-asserted-by":"crossref","first-page":"940","DOI":"10.1002\/psp4.12474","article-title":"Pharmacokinetics of capecitabine and four metabolites in a heterogeneous population of cancer patients: a comprehensive analysis","volume":"8","author":"Jacobs","year":"2019","journal-title":"CPT Pharmacometrics Syst Pharmacol"},{"issue":"7","key":"10.1016\/j.esmoop.2021.100125_bib20","doi-asserted-by":"crossref","first-page":"762","DOI":"10.1124\/dmd.32.7.762","article-title":"Bioactivation of capecitabine in human liver: involvement of the cytosolic enzyme on 5\u2019-deoxy-5-fluorocytidine formation","volume":"32","author":"Tabata","year":"2004","journal-title":"Drug Metab Dispos"},{"issue":"9","key":"10.1016\/j.esmoop.2021.100125_bib21","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1016\/j.ctrv.2015.06.001","article-title":"TAS-102, a novel antitumor agent: a review of the mechanism of action","volume":"41","author":"Lenz","year":"2015","journal-title":"Cancer Treat Rev"},{"issue":"6","key":"10.1016\/j.esmoop.2021.100125_bib22","doi-asserted-by":"crossref","first-page":"2327","DOI":"10.3892\/ijo.2015.2974","article-title":"Crucial roles of thymidine kinase 1 and deoxyUTPase in incorporating the antineoplastic nucleosides trifluridine and 2\u2019-deoxy-5-fluorouridine into DNA","volume":"46","author":"Sakamoto","year":"2015","journal-title":"Int J Oncol"},{"issue":"4","key":"10.1016\/j.esmoop.2021.100125_bib23","first-page":"292","article-title":"TAS-102 (Lonsurf) for the treatment of metastatic colorectal cancer. A concise review","volume":"15","author":"Zaniboni","year":"2016","journal-title":"Clin Colorectal Cancer"},{"issue":"6","key":"10.1016\/j.esmoop.2021.100125_bib24","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1177\/1758834015603313","article-title":"Therapeutic potential of TAS-102 in the treatment of gastrointestinal malignancies","volume":"7","author":"Peters","year":"2015","journal-title":"Ther Adv Med Oncol"},{"issue":"4","key":"10.1016\/j.esmoop.2021.100125_bib25","first-page":"310","article-title":"Safety report of TAS-102 in a patient with reduced DPD activity","volume":"18","author":"Bolzacchini","year":"2019","journal-title":"Clin Colorectal Cancer"},{"issue":"11","key":"10.1016\/j.esmoop.2021.100125_bib26","doi-asserted-by":"crossref","first-page":"3537","DOI":"10.1200\/JCO.1998.16.11.3537","article-title":"Toxicity of fluorouracil in patients with advanced colorectal cancer: effect of administration schedule and prognostic factors","volume":"16","author":"L\u00e9vy","year":"1998","journal-title":"J\u00a0Clin Oncol"},{"issue":"2","key":"10.1016\/j.esmoop.2021.100125_bib27","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1517\/14740338.2011.546342","article-title":"Capecitabine and hand-foot syndrome","volume":"10","author":"Saif","year":"2011","journal-title":"Expert Opin Drug Saf"},{"issue":"2","key":"10.1016\/j.esmoop.2021.100125_bib28","doi-asserted-by":"crossref","first-page":"E111","DOI":"10.15420\/ahhj.2010.8.2.111","article-title":"Angina induced by 5-fluorouracil infusion in a patient with normal coronaries","volume":"8","author":"Tajik","year":"2010","journal-title":"Am Heart Hosp J"},{"issue":"1","key":"10.1016\/j.esmoop.2021.100125_bib29","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1038\/bjc.1998.12","article-title":"The anti-cancer drug 5-fluorouracil is metabolized by the isolated perfused rat liver and in rats into highly toxic fluoroacetate","volume":"77","author":"Arellano","year":"1998","journal-title":"Br J Cancer"},{"issue":"6","key":"10.1016\/j.esmoop.2021.100125_bib30","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1080\/15257770802145496","article-title":"Selective protection by uridine of growth inhibition by 5-fluorouracil (5FU) mediated by 5FU incorporation into RNA, but not the thymidylate synthase mediated growth inhibition by 5FU-leucovorin","volume":"27","author":"Codacci-Pisanelli","year":"2008","journal-title":"Nucleosides Nucleotides Nucleic Acids"},{"issue":"1","key":"10.1016\/j.esmoop.2021.100125_bib31","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1111\/cas.14253","article-title":"Regulation of ATP-binding cassette subfamily B member 1 by snail contributes to chemoresistance in colorectal cancer","volume":"111","author":"Wang","year":"2020","journal-title":"Cancer Sci"},{"issue":"12","key":"10.1016\/j.esmoop.2021.100125_bib32","doi-asserted-by":"crossref","first-page":"1715","DOI":"10.2217\/pgs.10.159","article-title":"ABCB1 gene polymorphisms are associated with adverse reactions in fluoropyrimidine-treated colorectal cancer patients","volume":"11","author":"Gonzalez-Haba","year":"2010","journal-title":"Pharmacogenomics"},{"issue":"15","key":"10.1016\/j.esmoop.2021.100125_bib33","doi-asserted-by":"crossref","first-page":"5307","DOI":"10.1158\/0008-5472.CAN-11-0221","article-title":"ABCB5 identifies a therapy-refractory tumor cell population in colorectal cancer patients","volume":"71","author":"Wilson","year":"2011","journal-title":"Cancer Res"},{"issue":"1","key":"10.1016\/j.esmoop.2021.100125_bib34","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1158\/1535-7163.MCT-06-0529","article-title":"MRP8\/ABCC11 directly confers resistance to 5-fluorouracil","volume":"6","author":"Oguri","year":"2007","journal-title":"Mol Cancer Ther"},{"issue":"13","key":"10.1016\/j.esmoop.2021.100125_bib35","doi-asserted-by":"crossref","first-page":"1681","DOI":"10.1016\/S0959-8049(01)00174-5","article-title":"Thymidylate synthase (TS) and ribonucleotide reductase (RNR) may be involved in acquired resistance to 5-fluorouracil (5-FU) in human cancer xenografts in\u00a0vivo","volume":"37","author":"Fukushima","year":"2001","journal-title":"Eur J Cancer"},{"issue":"3","key":"10.1016\/j.esmoop.2021.100125_bib36","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1097\/CAD.0b013e328334d88a","article-title":"Thymidine phosphorylase expression in metastatic sites is predictive for response in patients with colorectal cancer treated with continuous oral capecitabine and biweekly oxaliplatin","volume":"21","author":"Petrioli","year":"2010","journal-title":"Anticancer Drugs"},{"issue":"17","key":"10.1016\/j.esmoop.2021.100125_bib37","doi-asserted-by":"crossref","first-page":"5880","DOI":"10.1158\/1078-0432.CCR-04-0169","article-title":"Thymidylate synthase gene polymorphism predicts toxicity in colorectal cancer patients receiving 5-fluorouracil-based chemotherapy","volume":"10","author":"Lecomte","year":"2004","journal-title":"Clin Cancer Res"},{"issue":"1","key":"10.1016\/j.esmoop.2021.100125_bib38","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1007\/s00280-017-3478-3","article-title":"DPYD\u22172A and MTHFR C677T predict toxicity and efficacy, respectively, in patients on chemotherapy with 5-fluorouracil for colorectal cancer","volume":"81","author":"Nahid","year":"2018","journal-title":"Cancer Chemother Pharmacol"},{"issue":"22","key":"10.1016\/j.esmoop.2021.100125_bib39","first-page":"5433","article-title":"Dihydropyrimidine dehydrogenase activity in human peripheral blood mononuclear cells and liver: population characteristics, newly identified deficient patients, and clinical implication in 5-fluorouracil chemotherapy","volume":"53","author":"Lu","year":"1993","journal-title":"Cancer Res"},{"issue":"19","key":"10.1016\/j.esmoop.2021.100125_bib40","doi-asserted-by":"crossref","first-page":"3155","DOI":"10.1080\/10826079708000481","article-title":"A\u00a0simple chromatographic method for the analysis of pyrimidines and their ehydrogenated metabolites","volume":"20","author":"Gamelin","year":"1997","journal-title":"J\u00a0Liq Chrom Relat Tech"},{"issue":"11 Pt 1","key":"10.1016\/j.esmoop.2021.100125_bib41","first-page":"5405","article-title":"Enzymes of uracil catabolism in normal and neoplastic human tissues","volume":"45","author":"Naguib","year":"1985","journal-title":"Cancer Res"},{"issue":"1","key":"10.1016\/j.esmoop.2021.100125_bib42","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1186\/s12885-020-06907-0","article-title":"DPD status and fluoropyrimidines-based treatment: high activity matters too","volume":"20","author":"Chamorey","year":"2020","journal-title":"BMC Cancer"},{"issue":"10","key":"10.1016\/j.esmoop.2021.100125_bib43","first-page":"2899","article-title":"Correlation between dihydropyrimidine dehydrogenase activity in peripheral mononuclear cells and systemic clearance of fluorouracil in cancer patients","volume":"52","author":"Fleming","year":"1992","journal-title":"Cancer Res"},{"issue":"11","key":"10.1016\/j.esmoop.2021.100125_bib44","doi-asserted-by":"crossref","first-page":"416","DOI":"10.3390\/ph13110416","article-title":"Association of 5-FU therapeutic drug monitoring to DPD phenotype assessment may reduce 5-FU under-exposure","volume":"13","author":"Dolat","year":"2020","journal-title":"Pharmaceuticals (Basel)"},{"issue":"4","key":"10.1016\/j.esmoop.2021.100125_bib45","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1097\/FTD.0000000000000768","article-title":"Phenotyping of uracil and 5-fluorouracil metabolism using LC-MS\/MS for prevention of toxicity and dose adjustment of fluoropyrimidines","volume":"42","author":"Tafzi","year":"2020","journal-title":"Ther Drug Monit"},{"key":"10.1016\/j.esmoop.2021.100125_bib46","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/j.jpba.2016.04.039","article-title":"Development and validation of a rapid and sensitive UPLC-MS\/MS method for determination of uracil and dihydrouracil in human plasma","volume":"126","author":"Jacobs","year":"2016","journal-title":"J\u00a0Pharm Biomed Anal"},{"key":"10.1016\/j.esmoop.2021.100125_bib47","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1016\/j.clinbiochem.2018.04.001","article-title":"DPD functional tests in plasma, fresh saliva and dried saliva samples as predictors of 5-fluorouracil exposure and occurrence of drug-related severe toxicity","volume":"56","author":"Neto","year":"2018","journal-title":"Clin Biochem"},{"issue":"11","key":"10.1016\/j.esmoop.2021.100125_bib48","doi-asserted-by":"crossref","first-page":"1415","DOI":"10.1038\/bjc.2017.94","article-title":"Pretreatment serum uracil concentration as a predictor of severe and fatal fluoropyrimidine-associated toxicity","volume":"116","author":"Meulendijks","year":"2017","journal-title":"Br J Cancer"},{"issue":"3","key":"10.1016\/j.esmoop.2021.100125_bib49","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1006\/geno.1998.5379","article-title":"Characterization of the human dihydropyrimidine dehydrogenase gene","volume":"51","author":"Wei","year":"1998","journal-title":"Genomics"},{"issue":"8","key":"10.1016\/j.esmoop.2021.100125_bib51","doi-asserted-by":"crossref","first-page":"1083","DOI":"10.1124\/dmd.118.081737","article-title":"Functional characterization of 21 allelic variants of dihydropyrimidine dehydrogenase identified in 1070 Japanese individuals","volume":"46","author":"Hishinuma","year":"2018","journal-title":"Drug Metab Dispos"},{"issue":"6","key":"10.1016\/j.esmoop.2021.100125_bib52","doi-asserted-by":"crossref","first-page":"640","DOI":"10.1038\/clpt.2013.172","article-title":"Clinical pharmacogenetics implementation consortium guidelines for dihydropyrimidine dehydrogenase genotype and fluoropyrimidine dosing","volume":"94","author":"Caudle","year":"2013","journal-title":"Clin Pharmacol Ther"},{"issue":"4","key":"10.1016\/j.esmoop.2021.100125_bib53","doi-asserted-by":"crossref","first-page":"754","DOI":"10.1016\/j.bbadis.2016.01.009","article-title":"Phenotypic and clinical implications of variants in the dihydropyrimidine dehydrogenase gene","volume":"1862","author":"van Kuilenburg","year":"2016","journal-title":"Biochim Biophys Acta"},{"issue":"5","key":"10.1016\/j.esmoop.2021.100125_bib54","doi-asserted-by":"crossref","first-page":"e0175998","DOI":"10.1371\/journal.pone.0175998","article-title":"New advances in DPYD genotype and risk of severe toxicity under capecitabine","volume":"12","author":"Etienne-Grimaldi","year":"2017","journal-title":"PLoS One"},{"key":"10.1016\/j.esmoop.2021.100125_bib55","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/j.ctrv.2016.08.002","article-title":"Improving safety of fluoropyrimidine chemotherapy by individualizing treatment based on dihydropyrimidine dehydrogenase activity \u2013 ready for clinical practice?","volume":"50","author":"Meulendijks","year":"2016","journal-title":"Cancer Treat Rev"},{"issue":"6","key":"10.1016\/j.esmoop.2021.100125_bib56","doi-asserted-by":"crossref","first-page":"931","DOI":"10.2217\/pgs.09.28","article-title":"Dihydropyrimidine dehydrogenase gene variation and severe 5-fluorouracil toxicity: a haplotype assessment","volume":"10","author":"Amstutz","year":"2009","journal-title":"Pharmacogenomics"},{"issue":"12","key":"10.1016\/j.esmoop.2021.100125_bib57","doi-asserted-by":"crossref","first-page":"2915","DOI":"10.1093\/annonc\/mdx411","article-title":"DPYD genotype-guided dose individualization to improve patient safety of fluoropyrimidine therapy: call for a drug label update","volume":"28","author":"Henricks","year":"2017","journal-title":"Ann Oncol"},{"issue":"4","key":"10.1016\/j.esmoop.2021.100125_bib58","doi-asserted-by":"crossref","first-page":"e597","DOI":"10.1002\/onco.13626","article-title":"Implementing DPYD\u22172A genotyping in clinical practice: the Quebec, Canada, experience","volume":"26","author":"Jolivet","year":"2021","journal-title":"Oncologist"},{"issue":"5","key":"10.1016\/j.esmoop.2021.100125_bib59","first-page":"359","article-title":"Is capecitabine safe in patients with gastrointestinal cancer and dihydropyrimidine dehydrogenase deficiency?","volume":"5","author":"Saif","year":"2006","journal-title":"Clin Colorectal Cancer"},{"issue":"2","key":"10.1016\/j.esmoop.2021.100125_bib60","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1007\/s10549-019-05144-9","article-title":"Clinical implementation of pre-treatment DPYD genotyping in capecitabine-treated metastatic breast cancer patients","volume":"175","author":"Stavraka","year":"2019","journal-title":"Breast Cancer Res Treat"},{"issue":"3","key":"10.1016\/j.esmoop.2021.100125_bib61","doi-asserted-by":"crossref","first-page":"742","DOI":"10.1158\/1535-7163.MCT-13-0878","article-title":"microRNAs miR-27a and miR-27b directly regulate liver dihydropyrimidine dehydrogenase expression through two conserved binding sites","volume":"13","author":"Offer","year":"2014","journal-title":"Mol Cancer Ther"},{"key":"10.1016\/j.esmoop.2021.100125_bib62","series-title":"Holland-Frei Cancer Medicine","article-title":"Pyrimidine Analogs","author":"Pizzorno","year":"2003"},{"key":"10.1016\/j.esmoop.2021.100125_bib63","author":"Defossez"},{"issue":"9","key":"10.1016\/j.esmoop.2021.100125_bib64","doi-asserted-by":"crossref","first-page":"2545","DOI":"10.1158\/0008-5472.CAN-13-2482","article-title":"Comparative functional analysis of DPYD variants of potential clinical relevance to dihydropyrimidine dehydrogenase activity","volume":"74","author":"Offer","year":"2014","journal-title":"Cancer Res"}],"container-title":["ESMO Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2059702921000843?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2059702921000843?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,30]],"date-time":"2025-10-30T20:26:00Z","timestamp":1761855960000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2059702921000843"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,6]]},"references-count":60,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2021,6]]}},"alternative-id":["S2059702921000843"],"URL":"https:\/\/doi.org\/10.1016\/j.esmoop.2021.100125","relation":{},"ISSN":["2059-7029"],"issn-type":[{"value":"2059-7029","type":"print"}],"subject":[],"published":{"date-parts":[[2021,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Issues and limitations of available biomarkers for fluoropyrimidine-based chemotherapy toxicity, a narrative review of the literature","name":"articletitle","label":"Article Title"},{"value":"ESMO Open","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.esmoop.2021.100125","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 The Author(s). Published by Elsevier Ltd on behalf of European Society for Medical Oncology.","name":"copyright","label":"Copyright"}],"article-number":"100125"}}